Literature DB >> 6220672

Norfloxacin disposition after sequentially increasing oral doses.

B N Swanson, V K Boppana, P H Vlasses, H H Rotmensch, R K Ferguson.   

Abstract

Single doses of norfloxacin (200, 400, 800, 1,200, and 1,600 mg) or placebo were administered orally at weekly intervals to 14 healthy male volunteers in a double-blind study. Norfloxacin was measured in serum and urine by high-pressure liquid chromatography with UV detection. The concentrations of this drug in serum peaked 1 to 2 h after each dose; the mean peak values for increasing doses were 0.75, 1.58, 2.41, 3.15, and 3.87 micrograms/ml. Mean area under the serum concentration-time curves for the first 12 h after each dose were 3.56, 6.26, 11.4, 16.1, and 19.7 micrograms . h/ml, respectively. The elimination half-life of norfloxacin was about 7 h and was similar for all doses. The concentrations of the drug in urine also peaked 1 to 2 h after dosage; mean peak values for increasing doses were 200, 478, 697, 992, and 1,045 micrograms/ml. Renal clearances approximated 285 ml/min. About 30% of each dose was excreted into urine as unmetabolized norfloxacin. Crystals of the drug were occasionally observed during microscopic examination of freshly voided urine collected after the 1,200- and 1,600-mg doses. Crystalluria was not encountered at lower doses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220672      PMCID: PMC186038          DOI: 10.1128/AAC.23.2.284

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.

Authors:  J Downs; V T Andriole; J L Ryan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

2.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  2 in total
  54 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 2.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 4.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

5.  Norfloxacin in the therapy of uncomplicated gonorrhea.

Authors:  B Romanowski; H Wood; J Draker; M C Tsianco
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Effects of two cations on gastrointestinal absorption of ofloxacin.

Authors:  M Martínez Cabarga; A Sánchez Navarro; C I Colino Gandarillas; A Domínguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

Authors:  R Wise; B Kirkpatrick; J Ashby; D J Griggs
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 10.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.